NMTC NEUROONE MEDICAL TECHNOLOGIES Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: NMTC

Price (delayed)

$3.56

Market cap

$30.69M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.85

Enterprise value

$27.98M

?
Relative Growth: Rel. Growth: 67
Relative Strength: Rel. Strength: 21
Relative Valuation: Rel. Valuation: 16
Relative Profitability: Rel. Profitability: 19
Highlights
The company's debt has shrunk by 55% YoY and by 16% QoQ
The EPS has grown by 37% year-on-year and by 18% since the previous quarter
NEUROONE MEDICAL TECHNOLOGIES's gross profit has decreased by 13% YoY but it has increased by 11% QoQ
The quick ratio is down by 37% QoQ
The gross margin is down by 22% YoY
Sector: Healthcare
Industry: Medical Devices
Peers: OBIO OM

Key stats

What are the main financial stats of NMTC

NMTC stock price

How has the NEUROONE MEDICAL TECHNOLOGIES stock price performed over time
Intraday
2.59%
1 week
-4.3%
1 month
-20.71%
1 year
-1.39%
YTD
-21.76%
QTD
-23.61%

Financial performance

How have NEUROONE MEDICAL TECHNOLOGIES's revenue and profit performed over time
Revenue
$9.72M
Gross profit
$5.3M
Operating income
-$7.07M
Net income
-$6.64M
Gross margin
54.5%
Net margin
-68.3%
The gross margin is down by 22% YoY
NMTC's operating margin is up by 17% from the previous quarter and by 3.2% YoY
NEUROONE MEDICAL TECHNOLOGIES's gross profit has decreased by 13% YoY but it has increased by 11% QoQ
The company's net margin rose by 13% QoQ and by 9% YoY

Price vs fundamentals

How does NMTC's price correlate with its fundamentals

Growth

What is NEUROONE MEDICAL TECHNOLOGIES's growth rate over time

Valuation

What is NEUROONE MEDICAL TECHNOLOGIES stock price valuation
P/E
N/A
P/B
5.58
P/S
3.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.88
The EPS has grown by 37% year-on-year and by 18% since the previous quarter
The P/B is 30% below the 5-year quarterly average of 7.8 and 8% below the last 4 quarters average of 5.9
NEUROONE MEDICAL TECHNOLOGIES's equity has decreased by 16% from the previous quarter
The price to sales (P/S) is 90% lower than the 5-year quarterly average of 31.8 and 18% lower than the last 4 quarters average of 3.7
NMTC's revenue is up by 12% since the previous quarter and by 11% year-on-year

Efficiency

How efficient is NEUROONE MEDICAL TECHNOLOGIES business performance
The return on equity has surged by 71% year-on-year and by 18% since the previous quarter
NMTC's ROA is up by 44% YoY and by 12% from the previous quarter
The company's return on invested capital rose by 20% QoQ and by 15% YoY
The ROS has grown by 13% since the previous quarter and by 9% year-on-year

Dividends

What is NMTC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NMTC.

Financial health

How did NEUROONE MEDICAL TECHNOLOGIES financials performed over time
NMTC's current ratio has surged by 106% year-on-year but it is down by 32% since the previous quarter
The total assets has surged by 76% year-on-year but it has declined by 8% since the previous quarter
The company's debt is 98% lower than its equity
NMTC's debt to equity has shrunk by 89% YoY
The company's debt has shrunk by 55% YoY and by 16% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.